Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Yao, 2008, One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States, J Clin Oncol, 26, 3063, 10.1200/JCO.2007.15.4377 2015 Caplin, 2015, Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoid, Ann Oncol, 26, 1604, 10.1093/annonc/mdv041 Pavel, 2016, ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site, Neuroendocrinology, 103, 172, 10.1159/000443167 Yao, 2016, Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study, Lancet, 387, 968, 10.1016/S0140-6736(15)00817-X 2016 2017 Fazio N, Buzzoni R, Delle Fave G, et al. Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the lung: a subgroup analysis of the phase 3 RADIANT-4 study. European Neuroendocrine Tumor Society 13th Annual Conference; March 9–11, 2016; Barcelona, Spain. Abstract P1. Sullivan, 2017, Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids, Eur J Cancer, 75, 259, 10.1016/j.ejca.2016.11.034 Cives, 2015, The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors, Drugs, 75, 847, 10.1007/s40265-015-0397-7 Kvols, 2012, Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study, Endocr Relat Cancer, 19, 657, 10.1530/ERC-11-0367 Wolin, 2015, Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues, Drug Des Devel Ther, 9, 5075, 10.2147/DDDT.S84177 Cives, 2015, Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors, Endocr Relat Cancer, 22, 1, 10.1530/ERC-14-0360 O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 2004 Dasari, 2017, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States, JAMA Oncol, 3, 1335, 10.1001/jamaoncol.2017.0589 Crona, 2013, Effect of temozolomide in patients with metastatic bronchial carcinoids, Neuroendocrinology, 98, 151, 10.1159/000354760 Mariniello, 2016, Long-term results of PRRT in advanced bronchopulmonary carcinoid, Eur J Nucl Med Mol Imaging, 43, 441, 10.1007/s00259-015-3190-7 Walter, 2016, Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors, Lung Cancer, 96, 68, 10.1016/j.lungcan.2016.03.018 Fazio, 2013, Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study, Chest, 143, 955, 10.1378/chest.12-1108 Halperin, 2017, Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study, Lancet Oncol, 18, 525, 10.1016/S1470-2045(17)30110-9 Litvak, 2016, Bronchial and thymic carcinoid tumors, Hematol Oncol Clin North Am, 30, 83, 10.1016/j.hoc.2015.09.003 Kulke, 2017, A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial, Ann Oncol, 28, 1309, 10.1093/annonc/mdx078 Chan, 2012, Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors, Endocr Relat Cancer, 19, 615, 10.1530/ERC-11-0382 Porta, 2011, Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma, Eur J Cancer, 47, 1287, 10.1016/j.ejca.2011.02.014